Advertisement

Parents' Views on 3 Shot-Related Visits: Implications for Use of Adolescent Vaccines Like Human Papillomavirus Vaccine

      Objective

      Multidose adolescent-targeted vaccines, for example the human papillomavirus (HPV) vaccine, require parents and adolescents to have repeated interactions with the physician's office. We sought to evaluate parental views on participating in frequent vaccine-related encounters and their preferences for how these encounters should ideally be implemented.

      Methods

      A Web-based survey about a hypothetical 3-dose adolescent vaccine was provided to a national sample of 1025 US parents of adolescents (aged 9–17 years) in 2007.

      Results

      Survey completion rate among parents was 69%. Most (86%) were amenable to having their adolescent visit the provider's office at least 3 times in a year for vaccination. The highest proportion of parents (47%) preferred that the first dose be administered at a comprehensive doctor visit, followed by 2 nurse “shots-only” visits. However, many parents (30%) wanted each dose to be given as part of a comprehensive visit with a physician. The most commonly cited barriers included a belief that healthy adolescents needn't be seen frequently in the doctor's office (15%) and concerns about missing school (14%).

      Conclusions

      Compliance with multidose adolescent vaccines like HPV could require a shift in the expected frequency of health care visits. Our results suggest that most parents are amenable to more frequent adolescent vaccine-related visits, though the feasibility of implementing these visits within the current medical system remains to be determined.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Academic Pediatrics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bilukha O.O.
        • Rosenstein N.
        Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 2005; 54: 1-21
        • Broder K.R.
        • Cortese M.M.
        • Iskander J.K.
        • et al.
        Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 2006; 55: 1-34
        • Broder K.R.
        • Cohn A.C.
        • Schwartz B.
        • et al.
        Adolescent immunizations and other clinical preventive services: a needle and a hook?.
        Pediatrics. 2008; 12: S25-S34
      1. Gardasil [product information sheet]. Whitehouse Station, NJ: Merck & Co; 2006.

        • Markowitz L.E.
        • Dunne E.F.
        • Saraiya M.
        • et al.
        Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 2007; 56: 1-24
        • Giuliano A.R.
        • Salmon D.
        The case for a gender-neutral (universal) human papillomavirus vaccination policy in the United States: point.
        Cancer Epidemiol Biomarkers Prev. 2008; 17: 805-808
        • Rand C.M.
        • Szilagyi P.G.
        • Albertin C.
        • Auinger P.
        Additional health care visits needed among adolescents for human papillomavirus vaccine delivery within medical homes: a national study.
        Pediatrics. 2007; 120: 461-466
        • Stanberry L.R.
        • Spruance S.L.
        • Cunningham A.L.
        • et al.
        Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
        N Engl J Med. 2002; 347: 1652-1661
        • Wloch M.K.
        • Smith L.R.
        • Boutsaboualoy S.
        • et al.
        Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.
        J Infect Dis. 2008; 197: 1634-1642
        • Dempsey A.F.
        • Zimet G.D.
        • Davis R.L.
        • Koutsky L.
        Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV.
        Pediatrics. 2006; 117: 1486-1493
        • Mays R.M.
        • Sturm L.A.
        • Zimet G.D.
        Parental perspectives on vaccinating children against sexually transmitted infections.
        Soc Sci Med. 2004; 58: 1405-1413
        • Olshen E.
        • Woods E.R.
        • Austin S.B.
        • Luskin M.
        • Bauchner H.
        Parental acceptance of the human papillomavirus vaccine.
        J Adolesc Health. 2005; 37: 248-251
        • Gerend M.A.
        • Shepherd J.E.
        • Monday K.A.
        Behavioral frequency moderates the effects of message framing on HPV vaccine acceptability.
        Ann Behav Med. 2008; 35: 221-229
        • Kahn J.A.
        • Rosenthal S.L.
        • Jin Y.
        • et al.
        Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women.
        Obstet Gynecol. 2008; 111: 1103-1110
        • Brabin L.
        • Roberts S.A.
        • Stretch R.
        • et al.
        Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study.
        BMJ. 2008; 336: 1056-1058
        • Rosenthal S.L.
        • Rupp R.
        • Zimet G.D.
        • et al.
        Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitudes.
        J Adolesc Health. 2008; 43: 239-245
        • McCauley M.M.
        • Stokley S.
        • Stevenson J.
        • Fishbein D.B.
        Adolescent vaccination: coverage achieved by ages 13–15 years, and vaccinations received as recommended during ages 11–12 years, national health interview survey 1997–2003.
        J Adolesc Health. 2008; 43: 540-547
        • Centers for Disease Control and Prevention
        Vaccination coverage among adolescents aged 13–17 years—United States, 2007.
        MMWR Morb Mortal Wkly Rep. 2008; 57: 1100-1103
        • Zimet G.D.
        • Mays R.M.
        • Sturm L.A.
        • et al.
        Parental attitudes about sexually transmitted infection vaccination for their adolescent children.
        Arch Pediatr Adolesc Med. 2005; 159: 132-137
        • Bair R.M.
        • Mays R.M.
        • Sturm L.A.
        • et al.
        Acceptability to Latino parents of sexually transmitted infection vaccination.
        Ambul Pediatr. 2008; 9: 98
      2. Guiliano APJ, Male Quadrivalent HPV Vaccine Efficacy Trial Group. The efficacy of the quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV infection and HPV-related genital disease in young men. Abstract TC 2–11. Nice, France: European Research Organization on Genital Infection and Neoplasia (EUROGIN); 2008.

        • Baker L.
        • Wagner T.H.
        • Singer S.
        • Bundorf M.K.
        Use of the Internet and e-mail for health care information: results from a national survey.
        JAMA. 2003; 289: 2400-2406
        • Bleakley A.
        • Hennessy M.
        • Fishbein M.
        Public opinion on sex education in US schools.
        Arch Pediatr Adolesc Med. 2006; 160: 1151-1156
        • Davis M.M.
        • Fant K.
        Coverage of vaccines in private health plans: what does the public prefer?.
        Health Aff (Millwood). 2005; 24: 770-779
        • Middleman A.B.
        Adolescent immunizations: policies to provide a shot in the arm for adolescents.
        J Adolesc Health. 2007; 41: 109-118